United Therapeutics bags a new OK on Tyvaso, with blockbuster expectations; Gilead goes back to AbCellera’s well with a set of fresh targets

As expected, United Therapeutics {UTHR} snagged an OK from the FDA to sell the inhaled version of its blockbuster drug Tyvaso for a new indication: pulmonary hypertension associated with interstitial lung disease. And as expected, they immediately launched their new marketing effort after carefully laying the groundwork.

United COO Michael...

Click to view original post